COMP <GO>
DBD vs TMO // EV/EBITDA & P/E VALUATION
Diebold Nixdorf Incorporated (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: DBD 4
— TMO 7
▲ EV/EBITDA & P/E VALUATION LEADER: DBD
LAST: $59.14 (+1.84%) • MKT CAP: $1.99B
valuation
10.6x
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
valuation
30.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DBD VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | DBD | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 25.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.50% | 9.30% | +2.20 | DBD | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 10.6x | 30.4x | -19.80 | DBD | /valuation <GO> |
| Free Cash Flow Yield | 15.14% | 2.40% | +12.74 | DBD | /fcf-yield <GO> |
| Operating Margin | 6.40% | 17.40% | -11.00 | TMO | /operating-margins <GO> |
| Net Profit Margin | 2.50% | 15.10% | -12.60 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 1.50% | 3.90% | -2.40 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.24% | -0.24 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.79 | 4.50 | -2.71 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 27.7 | 62.9 | -35.22 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 19.5x | 36.3x | -16.80 | DBD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.99B | $262.22B | -$260.23B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | DBD REV | TMO REV | DBD GROSS % | TMO GROSS % | DBD FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.81B | $44.56B | 25.3% | — | $300.7M | $6.29B |
| FY 2024 | $3.75B | $42.88B | 24.5% | — | $149.2M | $7.27B |
| FY 2023 | — | $42.86B | — | — | — | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DBD // BETA —
TMO // BETA 0.94